TITLE

BTG GETS EXCLUSIVE LICENSE TO NEW CLASS OF CANCER DRUG

PUB. DATE
July 2004
SOURCE
Worldwide Biotech;Jul2004, Vol. 16 Issue 7, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the completion of a license and research collaboration agreement for a class of cancer drug between BTG and Cancer Research Technology Ltd. (CRT) in July 2004. Terms of agreement; Remarks from heads and CEO of BTG and CRT; Business operations of BTG and CRT.
ACCESSION #
13606236

 

Related Articles

  • BTG acquires exclusive license to new class of cancer drug.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p16 

    Reports on the research collaboration agreement of BTG Inc. with Cancer Research Technology Ltd. for the development of a new class of cancer drug. Terms under the agreement; Benefits of the deal for both companies; Significance of the deal for the pharmaceutical biotechnology industry.

  • BTG licenses new prostate cancer drug to Cougar Biotechnology.  // PharmaWatch: Cancer;June 2004, Vol. 3 Issue 6, p10 

    Reveals that BTG licensed Cougar Biotechnology's abiraterone acetate drug for the treatment of advanced prostate cancer. Other terms of the agreement.

  • BTG cashes in on BT's technology with optical device deal.  // Electronics Weekly;6/12/2002, Issue 2056, p1 

    Reports on the license agreements signed by BTG with four Japanese firms. Revenue generated by the deals; Features of the optical device developed by BT.

  • Forma skips tech transfer brokers. Moran, Nuala // Nature Biotechnology;Sep2013, Vol. 31 Issue 9, p777 

    The article reports on the move of biopharmaceuticals company Forma Therapeutics Inc. to struck a deal with Cancer Research Technology (CRT) Ltd. and short circuit the process of technology transfer.

  • Consortium Seeks New Cancer Drugs.  // Labmate UK & Ireland;Aug2013, Vol. 38 Issue 7, p14 

    The article reports on a cancer drug being developed by Cancer Research Technology, the University of Manchester and AstraZeneca, which will target a protein involved in DNA damage response.

  • United Kingdom : Cancer Research UK and Cancer Research Technology join forces with Astellas on Autophagy to find new Cancer Treatments.  // TendersInfo News;8/9/2014, p1 

    The article reports on the collaboration between cancer research organization Cancer Research Technology (CRT) Ltd. and pharmaceutical firm Astellas Pharma Inc., for the development and testing of new drugs as treatment for cancer, particular on treatment for pancreatric cancer.

  • BTG bags $44m in chip license revenues despite shift in focus.  // Electronics Weekly;5/30/2007, Issue 2290, p5 

    The article reports that BTG Inc. received $44m in semiconductor licensing deals last year and is looking for more, even though it is de-emphasizing the semiconductor side of its operations. A spokesman for BTG said that the company is focusing on life sciences and wants to monetize the patents...

  • ValiRx and CRT sign licensing agreement for prostate cancer compound.  // PharmaWatch: Cancer;Aug2008, Vol. 7 Issue 8, p14 

    The article reports on the license agreement between ValiRx and Cancer Research Technology Ltd. (CRT) to assess the VAL201, a new prostate cancer compound. Under the terms of agreement, ValiRx has a period of 12 months to complete the preclinical regulatory development of VAL201 including...

  • CRUK Acts as Funnel, Bringing New Biotech Products to Market. Moran, Nuala // BioWorld International;8/24/2011, Vol. 16 Issue 34, p2 

    This article explains that British charity Cancer Research UK (CRUK) is creating new routes to commercialization of abiraterone, a treatment for prostate cancer it discovered and patented in 1993, for the 550 million U.S. dollars of research it funds each year. The drug has received approval...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics